Postapproval observational studies of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation

JAMA - Journal of the American Medical Association

Volumn 317, Issue 11, 2017, Pages 1115-1116

  Potpara, Tatjana S ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COMORBIDITY; DEYO CHARLSON COMORBIDITY SCORE; DISEASE REGISTRY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; MEDICATION COMPLIANCE; NOTE; PATIENT COMPLIANCE; POSTAPPROVAL OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; STUDY DESIGN; CHEMICALLY INDUCED; COMPLICATION; INFORMATION PROCESSING; OBSERVATIONAL STUDY; PATIENT SELECTION; REGISTER; STANDARDS; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; DATA COLLECTION; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PATIENT SELECTION; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RIVAROXABAN; STROKE; WARFARIN;

EID: 85016099869     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.1152     Document Type: Note

References (10)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation. Lancet. 2014;383(9921):955-962.
2. Carmo J, Moscoso Costa F, Ferreira J, MendesM. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016; 116(4):754-763.
3. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation. BMJ. 2016;353:i3189.
4. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban vs warfarin in nonvalvular atrial fibrillation. J AmHeart Assoc. 2016;5(6):pii e003725.
5. Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;116(5):975-986.
6. Staerk L, Fosbol EL, Lip GY, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation [published online October 14, 2016]. Eur Heart J. doi:10.1093 /eurheartj/ehw496
7. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176(11):1662-1671.
8. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban vs warfarin and dabigatran in atrial fibrillation. Pharmacoepidemiol Drug Saf. 2016;25: 1236-1244.
9. Maura G, Blotiere PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban vs vitamin k antagonists. Circulation. 2015;132:1252-1260.
10. Raparelli V, ProiettiM, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(2):209-218.